#165 - AMA #24: Deep dive into blood glucose: why it matters, important metrics to track, and superior insights from a CGM

Episode Summary

Executive Summary: This AMA sneak peek argues that glucose health in non-diabetic people is better assessed with continuous glucose monitoring (CGM) and oral glucose tolerance testing than with fasting glucose or HbA1c alone. Peter Atiyah emphasizes glucose as a continuum, prioritizing lower average glucose, less variability, and fewer peaks as markers of better metabolic health and future medicine.

Main Topics: Why CGM matters beyond diabetes (Priority: 5/5): The episode centers on using CGM in people without type 1 or type 2 diabetes to understand real-world glucose homeostasis, not just diagnose disease. Limitations of HbA1c (Priority: 5/5): Atiyah explains that HbA1c can mislead because red blood cell lifespan and blood loss conditions can distort the estimate of average glucose. Glucose as a continuum (Priority: 5/5): He rejects rigid cutoffs that label people as normal or abnormal based only on HbA1c thresholds, arguing that metabolic risk exists on a spectrum. What CGM reveals (Priority: 4/5): CGM provides continuous, practical data on average glucose, variability, peaks, and nadirs, offering a more direct view of glucose behavior than snapshot labs. Targets for optimal glucose control (Priority: 5/5): Atiyah states that lower average glucose, lower standard deviation, and fewer peaks are all desirable, even in non-diabetic individuals. Future of routine metabolic monitoring (Priority: 4/5): He envisions CGM becoming part of standard primary care, similar to home blood pressure monitoring, to guide prevention and longevity-focused care.

Key Arguments: HbA1c is useful but can be misleading because it depends on red blood cell lifespan, which varies with bleeding, anemia patterns, and conditions like beta thalassemia minor. A person can be non-diabetic yet still have suboptimal glucose control; therefore, 'normal' should not be treated as a binary category. CGM is superior for assessing glucose homeostasis because it directly measures glucose trends over time rather than inferring them from hemoglobin glycation. Lower average glucose is better, even among people far from the diabetes threshold. Glucose variability matters independently of average glucose; two people with the same mean glucose can have different risk profiles if one has a higher standard deviation. Glucose peaks are specifically undesirable and should be minimized, not just average glucose. The mainstream medical system relies too heavily on simplified thresholds and may be behind where future preventive medicine is headed. CGM data can be used to reverse-engineer an imputed HbA1c, but the direct CGM-derived measure is more informative. Routine wearables and home monitoring may eventually make metabolic assessment more personalized and proactive.

Data Points: Type 2 diabetes HbA1c threshold: > 6.5% - Defined as the diagnostic cutoff for type 2 diabetes in the discussion. Prediabetes HbA1c range: 5.7% to 6.4% - Referenced as the conventional range that Atiyah считает still too simplistic. Approximate average glucose at HbA1c 6.5%: ~130 mg/dL - Atiyah estimates the average blood glucose corresponding to the diabetes threshold. CGM sampling frequency: Every 5 minutes - He explains that the CGM sends a new glucose reading to the phone every five minutes. Atiyah's 24-hour average glucose: ~90 mg/dL - Example from his own CGM data over the prior 24 hours. Atiyah's glucose standard deviation: ~9 to 10 mg/dL - Reported as his recent CGM variability measure. Atiyah's peak glucose: 102 mg/dL - Highest value in his last 24 hours of CGM data. Atiyah's nadir glucose: 77 mg/dL - Lowest value in his last 24 hours of CGM data. No peaks above: 140 mg/dL - He notes his CGM data showed no excursions above this level. HbA1c vs CGM discrepancy in Atiyah: 0.5 to 0.8 percentage points higher on HbA1c - He says his HbA1c typically overstates his true average glucose because of beta thalassemia minor. Highest HbA1c Atiyah reports: 5.8% - Personal example of his measured HbA1c. Lowest HbA1c Atiyah reports: 5.1% - Personal example of his measured HbA1c. CGM use duration: Nearly 6 years - Atiyah says he has worn a CGM for almost six years. Typical red blood cell lifespan: About 90 days - Used to explain why HbA1c reflects longer-term glucose exposure.

Pivotal Quotes: "Lower average blood glucose is better." — Peter Atiyah: Core thesis on glucose optimization in non-diabetic people. "The difference between a snapshot and a movie." — Bob Kaplan: Describing the advantage of CGM over HbA1c or fasting glucose. "I think oversimplification is erroneous." — Peter Atiyah: Critique of rigid HbA1c-based normal/abnormal categories.

Implications: Listeners are encouraged to think of glucose health as a spectrum and to use CGM for more nuanced prevention. The episode points toward a future where metabolic monitoring is routine, personalized, and more predictive than standard lab cutoffs.